2017 American Transplant Congress
The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction.
The aetiology of renal transplant dysfunction is varied, and diagnosis often relies upon transplant biopsy, an invasive procedure that carries significant risk. Availability of a…2017 American Transplant Congress
Transcriptomic Analysis Revealed a Fibrotic Role of Epithelial Cells Originated from the Recipient in Kidney Transplant.
Renal fibrosis is one of major causes for chronic renal dysfunction in kidney diseases and graft loss in kidney transplant. With an aim to better…2017 American Transplant Congress
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.
IntroductionLeucopenia is a growing problem with increasing immunosuppression (IS) in kidney transplantation. Reducing IS in the face of leucopenia is a concern due to the…2017 American Transplant Congress
Outcome of Adult Living Donor Renal Transplants in Different Era: Analysis of UNOS Database.
Surgery, State University New York, Syracuse, NY
Background:Living donation is the potential solution to increasing donor donor shortage. This retrospective analysis of UNOS database analyses the outcome of living donor transplantation across…2017 American Transplant Congress
Lack of Specificity of LC-MS/MS Based Urinary Biomarkers for Polyomavirus BK Nephropathy (BKPyVN).
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) based studies have suggested that BKPyVN leads to the excretion of virus-specific urinary peptides which can serve as diagnostic markers…2017 American Transplant Congress
TGF-β1 Induces Transplant Kidney Interstitial Fibrosis Through Endothelial-to-Mesenchymal Transition via TGF-β/Smad and Akt/mTOR/p70S6K Pathways.
Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Background: Chronic allograft dysfunction (CAD) induced by kidney interstitial fibrosis is the main cause of allograft failure in kidney transplantation. Studies suggested that endothelial-to-mesenchymal transition…2017 American Transplant Congress
Prospective Monitoring of De Novo Donor-Specific Antibodies: Incidence, Clinical Outcomes and Dynamic Changes Over 5 Years After Kidney Transplantation.
Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, Bronx
Background: We aimed to investigate the incidence and dynamic changes of de novo donor-specific-antibodies (dnDSA) after kidney transplantation and clinical outcomes.Methods: This is a prospective…2017 American Transplant Congress
Gene Editing of Keap1/Nrf2 in Human T Cells Using CRISPR-Cas9 to Improve Outcome from Ischemia Reperfusion Injury and Other T Cell Mediated Diseases.
Background: T lymphocytes are important mediators of ischemia reperfusion injury (IRI) during organ transplantation. Using genetically engineered mice, we demonstrated that augmentation of Nrf2 dependent…2017 American Transplant Congress
Long-Term Outcomes Among Slow versus Delayed or Immediate Graft Function Kidney Transplant Recipients: A Single-Center Experience.
Transplant Institute, Henry Ford Health System, Detroit, MI
Purpose: To compare and evaluate short and long-term outcomes for kidney transplant recipients (KTR) with slow graft function (SGF) versus delayed (DGF) or immediate (IGF)…2017 American Transplant Congress
National Variation in US Kidney Transplant Induction Therapy.
Antibody induction (IND) therapy in kidney transplantation (KTx) reduces acute rejection risk but adds to transplant cost. Currently, only IL2 Receptor antibodies (IL2R-Ab) have FDA…
- « Previous Page
- 1
- …
- 372
- 373
- 374
- 375
- 376
- …
- 531
- Next Page »